BI/Lilly’s Jardiance To Face Off With AstraZeneca’s Farxiga In CKD After EU Nod

 
• By Ayisha Sharma

The SGLT2 inhibitor has won European approval for the treatment of chronic kidney disease and while rival AstraZeneca’s Farxiga has had a two-year head start in the space, Boehringer and Lilly could come out on top given Jardiance’s stronger sales records to date.  

graphic illustration of kidneys
Chronic Kidney Disease Affects 850 Million People Worldwide • Source: Shutterstock
Key Takeaways:

  • Jardiance has beaten Farxiga in sales to date despite the lack of a CKD indication.

  • There are around 47 million people with CKD in Europe and 850 million worldwide.

  • Jardiance’s patent protection should last well into the late 2020s in contrast to Farxiga.

Boehringer Ingelheim GmbH and partner Eli Lilly and Company’s Jardiance has won a European Commission thumbs up for the treatment of adults with chronic kidney disease (CKD), opening up a market that has

Jardiance (empagliflozin) is a key growth driver for the partners, with full-year 2022 sales growing by 48% to €5.83bn ($6.46bn)

More from Genitourinary

More from Therapy Areas